Elelyso Side Effects Center

Last updated on RxList: 9/16/2022
Elelyso Side Effects Center

Medical Editor: John Cunha, DO, FACOEP

What Is Elelyso?

Elelyso (taliglucerase alfa) for injection is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for adults with a confirmed diagnosis of type 1 Gaucher disease.

What Are Side Effects of Elelyso?

Common side effects of Elelyso include:

Some people receiving an Elelyso injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your doctor if you feel dizzy, nauseated, anxious, lightheaded, weak, tired, or have a sudden headache, red skin rash, fast or uneven heartbeats, chest pain or tightness, or buzzing in your ears during the injection of Elelyso. These side effects of Elelyso could occur up to 24 hours after your injection.

Seek medical care or call 911 at once if you have the following serious side effects:

  • Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;
  • Serious heart symptoms such as fast, irregular, or pounding heartbeats; fluttering in your chest; shortness of breath; and sudden dizziness, lightheartedness, or passing out;
  • Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors.

This document does not contain all possible side effects and others may occur. Check with your physician for additional information about side effects.

Dosage for Elelyso

Elelyso is dosed as 60 Units/kg administered every other week as a 60-120 minute intravenous infusion. Dosage adjustments may be made based on achievement and maintenance of each patient's therapeutic goals.

What Drugs, Substances, or Supplements Interact with Elelyso?

Elelyso may interact with other drugs. Tell your doctor all medications you use.

Elelyso During Pregnancy and Breastfeeding

There are no adequate and well controlled studies in pregnant women. Women who are pregnant or plan to become pregnant should talk to their doctors about potential benefits and risks. It is unknown if Elelyso passes into breast milk. Consult your doctor before breastfeeding.

Additional Information

Our Elelyso Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Elelyso Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Some people receiving a taliglucerase alfa injection have had a reaction when the medicine was injected, or up to 3 hours later. Tell your caregivers right away if you have:

  • dizziness or feeling like you might pass out;
  • chest tightness, wheezing;
  • swelling in your face;
  • cough, throat irritation;
  • flushing (warmth, redness, or tingly feeling);
  • nausea, vomiting;
  • skin rash, itching, or redness.

Common side effects may include:

  • headache;
  • rash, itching, warmth or tingly feeling;
  • dizziness or tired feeling;
  • nausea, stomach pain, vomiting; or
  • joint pain, back pain, pain in your arms or legs.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Elelyso Professional Information

SIDE EFFECTS

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Clinical Trials Of ELELYSO As Initial Therapy

Clinical Trial in Patients 19 Years and Older

The safety of ELELYSO at dosages of either 30 units/kg (n=16) or 60 units/kg (n=16) every other week was assessed in 32 adult treatment-naive patients (aged 19 to 74 years) with Type 1 Gaucher disease in a 9-month double-blind, randomized clinical trial.

Table 1: Adverse Reactions in ≥5% of Treatment-Naive Adult Patients Treated with ELELYSO

Preferred Term Treatment-Naive Adults (N=32)
n (%)
Headache 6 (19)
Arthralgia 4 (13)
Fatigue 3 (9)
Nausea 3 (9)
Dizziness 3 (9)
Abdominal pain 2 (6)
Pruritus 2 (6)
Flushing 2 (6)
Vomiting 2 (6)
Urticaria 2 (6)

Clinical Trial in Patients 16 Years and Younger

The safety of ELELYSO at dosages of either 30 units/kg (n=4) or 60 units/kg (n=5) every other week was assessed in 9 pediatric treatment-naive patients (aged 2 to 13 years) with Type 1 Gaucher disease in a 12-month randomized clinical trial.

The most common adverse reaction (≥10%) was vomiting, which occurred in 4 of 9 patients. Two patients developed hypersensitivity reactions; one patient experienced severe vomiting and gastrointestinal inflammation, and 1 experienced mild throat irritation and chest discomfort. Both patients responded to treatment with antihistamines and continued ELELYSO treatment.

Clinical Trial In Patients Switching From Imiglucerase Treatment To ELELYSO

The safety of ELELYSO was assessed in 31 patients (26 adult and 5 pediatric patients), ages 6 to 66 years old, with Type 1 Gaucher disease who had previously been receiving treatment with imiglucerase for a minimum of 2 years. ELELYSO was administered for 9 months at the same number of units as each patient’s previous imiglucerase dose.

Table 2: Adverse Reactions in ≥10% of Patients Switched from Imiglucerase to ELELYSO (after 9 months on treatment)

Preferred Term Patients Switched from Imiglucerase
(N=31; 26 adults and 5 children)
n (%)
Arthralgia 4 (13)
Headache 4 (13)
Pain in extremity 3 (10)

Immunogenicity

As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other taliglucerase alfa products may be misleading.

Anti-Drug Antibodies (ADA)

In a clinical trial of treatment-naive adults, 17 (53%) of 32 patients developed ADA during treatment with ELELYSO, and 2 (6%) of 32 patients tested positive for ADA at baseline prior to ELELYSO treatment. Of the 17 patients who developed ADA during ELELYSO treatment, 6 patients (35%) developed hypersensitivity reactions, 2 of whom met criteria for anaphylaxis. Two of the 17 patients who developed ADA during ELELYSO treatment discontinued treatment due to hypersensitivity reactions, one of whom had met criteria for anaphylaxis. Of the 2 patients who tested positive for ADA prior to initiation of ELELYSO treatment, one patient developed a hypersensitivity reaction during the first dose of ELELYSO and withdrew from the study. The second patient did not experience a hypersensitivity reaction.

In a clinical trial of treatment-naive pediatric patients, 2 (22%) of 9 patients developed ADA during treatment with ELELYSO, and one of 9 patients was ADA-positive prior to initiation of ELELYSO. Two of these 3 patients experienced hypersensitivity reactions (1 who developed ADA during treatment and became negative after Week 12 and 1 who was ADA-positive at baseline and became ADA negative after Week 8) and continued treatment with ELELYSO. The third patient who developed ADA during treatment and continued to be ADA-positive until study completion at Week 52 did not experience a hypersensitivity reaction.

In clinical trials of 31 patients (26 adult and 5 pediatric patients) who switched from imiglucerase to ELELYSO treatment, 5 adults (16% of patients) developed ADA during treatment with ELELYSO. Four additional patients (13%, 2 adults and 2 children) tested positive for ADA at baseline but became ADA-negative after the switch to ELELYSO; one of these adult patients subsequently developed ADA to ELELYSO. Two adult patients (1 patient who developed ADA after the switch and 1 who was ADA positive at baseline) experienced hypersensitivity reactions. Both patients continued treatment with ELELYSO.

The relationship between ADA and hypersensitivity reactions is not fully understood. Monitoring for ADA to ELELYSO may be useful in ADA positive patients or in patients who have experienced hypersensitivity reactions to ELELYSO or other enzyme replacement therapies.

Neutralizing Antibodies

Thirty (30) of the 31 adult and pediatric patients who developed ADA to ELELYSO during treatment or tested positive for ADA at baseline were evaluated for neutralizing activity of the ADA in the mannose receptor binding and enzyme activity assays. Nineteen (63%) of the 30 patients had neutralizing antibodies capable of inhibiting mannose receptor binding of ELELYSO. Eight of these 19 patients had neutralizing antibodies capable of inhibiting the enzymatic activity of ELELYSO. Available data do not indicate a clear relationship between the presence of mannose receptor binding neutralizing antibodies or neutralizing antibodies capable of inhibiting the enzymatic activity of ELELYSO and the therapeutic response to ELELYSO.

Other Antibodies

Nine (29%) of the 31 adult and pediatric patients who developed ADA to ELELYSO during treatment or tested positive for ADA at baseline also developed antibodies against plant-specific glycans in ELELYSO.

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of ELELYSO. Because these reactions include those reported voluntarily from a population of uncertain size in addition to those from postmarketing studies, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:

  • Gastrointestinal disorders: Vomiting, diarrhea
  • General disorders and administration site conditions: Fatigue
  • Immune system disorders: Anaphylaxis [see WARNINGS AND PRECAUTIONS], Type III immune-mediated fixed drug eruption
  • Musculoskeletal and connective tissue disorders: Back pain

DRUG INTERACTIONS

No Information Provided

Read the entire FDA prescribing information for Elelyso (Taliglucerase Alfa)

© Elelyso Patient Information is supplied by Cerner Multum, Inc. and Elelyso Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors